CA
NZ
UK
AU
IND
US
● The consensus 12-month price target is $82.70, implying about 18.9% upside.
● The consensus 12-month price target is $159.85, implying about 2.3% upside.
● The consensus 12-month price target is $702.38, implying about 25.3% upside.
● The consensus 12-month price target is $478.53, implying about 12.2% upside.
● The consensus 12-month price target is $368.71, implying about 59.0% upside.
● The consensus 12-month price target is $394.98, implying about 8.67% downside.
● The company suspended its fiscal 2026 revenue guidance of $110 million to $115 million.
● No company-specific news was reported for Myriad.
● Elevated Treasury yields hit long-duration and clinical-stage health-care stocks.
● The 10-year Treasury yield ended near 5.1 after topping 5.30 earlier in October.
Please wait processing your request...